A Randomized Double Blind Phase II trial of Surgery, Radiation Therapy plus Temozolomide and Pembrolizumab with and without HSPPC-96 in patients with newly diagnosed Glioblastoma (GBM)

February 19, 2019
https://clinicaltrials.gov/ct2/show/NCT03018288
Cancer - Brain
Principal Investigator: Tobias Walbert, MD

 Radiation Therapy, Temozolomide, Pembrolizumab, HSPPC-96, Glioblastoma

Accepting Participants